SB 202190 (hydrochloride)

SB 202190 hydrochloride is a selective p38 MAP kinase inhibitor with IC₅₀s of 50 nM and 100 nM for p38α and p38β2, respectively. SB 202190 hydrochloride binds to the ATP pocket of the active recombinant human p38 kinase with a K_d of 38 nM. SB 202190 hydrochloride has anti-cancer activity^[1][2]. SB202190 hydrochloride induces autophagy^[3]. In Vitro: SB 202190 (0-10 μM; 0-72 hours) hydrochloride attenuates growth of a subgroup of CRC cell lines such as RKO, CACO2 and SW480 in a dose- and time-dependent manner^[1].
SB 202190 hydrochloride strongly inhibited colony formation and anchorage-independent growth (10 μM for 7-10 days) and elevated apoptotic cell death (10 μM for 72 h) in this same subset of CRC lines (RKO, CACO2 and SW480)^[2].
In RKO, CACO2 and SW480 cells, SB 202190 (10 μM; 2 hours) hydrochloride abrogates phosphorylation of S6K1(T389) and S6(S235/236), but not AKT(S473), indicating that p38i selectively blocks mTORC1 signaling^[2]. In Vivo: SB 202190 (5 mg/kg; intraperitoneal injection; daily for 10-12 days) hydrochloride shows inhibition of tumor cell survival and tumor growth^[2].